Bioquark, develops biologics for complex regeneration and disease reversion, and biotechnology company Revita Life Sciences, focuses on translational therapeutic applications of autologous stem cell therapy.
In combination, the companies will focus on novel approaches to the restoration of function in spinal cord injury, explains a media release from Bioquark Inc.
Something the companies will study is the ability of amphibians to repair, regenerate, and remodel portions of their spinal cord following substantial trauma.
“We are very excited about this collaboration with Revita Life Sciences,” says Ira S. Pastor, CEO of Bioquark Inc, in the release. “The natural synergy of our cellular and biologic to applications of regenerative medicine make for novel and transformational opportunities in spinal cord injury resolution.”
Himanshu Bansal, MD, PhD, managing director of Revita Life Sciences, states in the release that the company looks forward to working closely with Bioquark Inc on this initiative.
“The ability to merge cellular and biologic approaches represents the next evolutionary step in achieving complete regeneration and return of full functionality in this devastating disease,” he adds.
[Source(s): Bioquark Inc, PRWeb]